Stockreport

ARCA biopharma Updates Special Protocol Assessment Request to FDA for Gencaro Phase 3 Atrial Fibrillation Clinical Trial

ARCA biopharma, Inc.  (ABIO) 
US:NASDAQ Investor Relations: arcabio.com/investors
PDF Phase 3 atrial fibrillation trial planned in population with no effective or FDA approved therapiesPRECISION-AF, planned Phase 3 clinical trial in patients with genotype [Read more]